Podcasts about molecular immunology

In this episode, I chatted with Dr. Kaitlyn Sadtler, who is pushing the boundaries of biomedical science. Co-hosted with HHMI Gilliam Fellow and ChemE PhD Candidate Sydney Floryanzia, we talk about their groundbreaking research, the twists and turns of their scientific journeys, and the power of collaboration in tackling big challenges.More on Dr. Sadtler, per the NIBIB:Kaitlyn Sadtler, Ph.D. joined NIBIB as an Earl Stadtman Tenure-Track Investigator and Chief of the Section for Immunoengineering in 2019. Prior to her arrival to the NIH, she completed a postdoctoral fellowship at the Massachusetts Institute of Technology with Daniel Anderson, Ph.D. and Robert Langer, Ph.D., focusing on the molecular mechanisms of medical device fibrosis. During her time at MIT, Dr. Sadtler was awarded an NRSA Ruth L Kirschstein Postdoctoral Fellowship, was listed on BioSpace's 10 Life Science Innovators Under 40 To Watch and StemCell Tech's Six Immunologists and Science Communicators to Follow. In 2018, she was named a TED Fellow and delivered a TED talk which was listed as one of the 25 most viewed talks in 2018. She was also elected to the 2019 Forbes 30 Under 30 List in Science, selected as a 2020 TEDMED Research Scholar, and received multiple other awards. Dr. Sadtler received her Ph.D. from the Johns Hopkins University School of Medicine where her thesis research was published in Science magazine, Nature Methods, and others. She was recently featured in the Johns Hopkins Medicine Magazine as an alumna of note. Dr. Sadtler completed her bachelor's degree summa cum laude at the University of Maryland Baltimore County, followed by a postbaccalaureate IRTA at the Laboratory of Cellular and Molecular Immunology at NIAID.

In this episode I'm going to play devil's advocate and look at the flaws on the left of the political spectrum. I am always trying to challenge my biases and poke holes in my positions by listening to opposing opinions. I have been butting heads with a UK professor over social media on several issues recently as he has been posting what I would consider biased right wing positions and I have been challenging him. We are both in agreement on many issues, however, that may come as a surprise to those people on the left. This is a job for The Rational View. Dr. Anton Van Der Merwe is a Professor of Molecular Immunology at the University of Oxford. He has been on the left his entire life from membership of the ANC, while in South Africa, to membership of the Labour Party since living in the U.K. He is also a passionate environmentalist. He has recently expressed  dismay at how the left and environmental groups have abandoned science and replaced it with dogma. Look for me on Youtube and Instagram or join the discussion on Facebook.

Dr. Wilfried Ellmeier is a Co-Chair of the Scientific Planning Committee at the International Union of Immunological Societies (IUIS) and Professor of Immunobiology and Head of the Institute of Immunology at the Medical University of Vienna. Dr. Laurence Zitvogel is a Keynote Speaker at IUIS 2025 and a Professor and Group Leader at Gustave Roussy. Dr. Dan Littman is also a Keynote Speaker at IUIS 2025 and Professor of Cell Biology and Helen L. and Martin S. Kimmel Professor of Molecular Immunology at NYU Langone. This episode features a discussion on  the upcoming IUIS 2025 Congress taking place August 17-22 in Vienna, Austria. They talk about what to expect at the meeting, highlights from this year's program, and where to explore in Vienna.

References Cellular & Molecular Immunology. 2018. volume 15, pages 676–684. Stem Cells Int. 2020: 1047896. Published online Jul 8 Cancer Science. 2014. June.105(9) --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support

Genetics is the transcript of your own personal health. We often perceive it as something that dictates that health issues are hereditary but the truth is that no one was born with chronic illnesses. In what way should we then perceive and interpret genetics?In this episode, Dr. Krista Kostroman is joined by Dr. Mansoor Mohammed, PhD. Dr. Mansoor is one of the founding members of The DNA Company as he had committed his life into studying genetics and all fields that revolve around it. He is a recognized authority in the fields of medical genomics and personalized medicine. He is the holder of several patents in the general fields of molecular diagnostics and genomics research. Dr. Mohammed completed his doctoral dissertation at the University of Guelph, Canada, majoring in both Molecular Immunology and Transgenic Technologies. He completed postdoctoral training in Clinical Cytogenetics at both UCLA and Baylor College of Medicine.Prior to becoming the scientific founder of The DNA Company, Dr. Mohammed co-founded Younique Genomics, served as the President and CEO of CombiMatrix Diagnostics—where he oversaw the development of one of the most comprehensive genomics testing menus in the diagnostic industry—and was the Director of Advanced Technologies at Quest Diagnostics, where he was honored with the Medical Innovation Award, the highest accolade given for excellence in medical research. Prior to his role at Quest Diagnostics, Dr. Mohammed was a founder and Director of Research and Development at Spectral Genomics. At Spectral Genomics, Dr. Mohammed pioneered the development of commercial Comparative Genomic Hybridization (CGH) array technologies and was responsible for the design and launch of the industry's first commercially available CGH arrays.Together, Dr. Krista and Dr. Mansoor go through the different stages and understandings of DNA that Dr. Mansoor went through - calling this the four epochs of his career.During the first epoch, Dr. Mansoor invented this whole genome technology where he studied human antibodies, and looked into animal models in order to deepen the study on the human's genetic makeup. This led him to founding companies such as Spectral Genomics and with the knowledge that they had at that time, they were able to focus on what was broken with the human body and used the study of DNA to find solutions to this. Moving on to 2011, he entered the second epoch of his career where he was questioned why they do not delve further than what was broken. This initiated Dr. Mansoor to dive deeper and study genomics with the addition of functional genomics. After continually studying what is unknown regarding a person's genomics, then comes the birth of The DNA Company. This story showcases how our clinicians today are able to prevent any possible illness by looking into a person's unique genetic makeup - even down to the body's smallest nuances.Onto the third epoch, the amount of information gathered must be handled with care so as not to dilute it in a soundbite that suggests that science is binary but rather give science its due right. This was when he realized that there was more to be done and stepped away to focus on studying yet continually serving people.Lastly, the fourth epoch dives into the study of hormone replacement and the continuous journey of advocating and researching for optimal human health, nutrition, lifestyle, and environment. ▬▬▬▬▬▬▬▬▬▬Keep yourself up to date on The DNA Talks Podcast! The DNA Talks Podcast Instagram https://www.instagram.com/dnatalkspodcast/Dr. Krista Kostroman's Official Instagram Page https://www.instagram.com/drkostromanofficial/This episode may also be viewed on YouTube

In the wake of my father's recent cancer diagnosis, my focus has sharpened on the critical realm of early cancer detection. This unexpected event injected a surge of urgency into my unyielding quest for preventive wellness, leading me back to the brilliant Dr. Ahvie Herskowitz. Embark on a journey into preventive health as I reunite with Dr. Ahvie, the founder of Anatara Medicine, one of the most comprehensive IV treatment centers in Northern California. The multidisciplinary integrative center in San Francisco treats some of the most difficult chronic health conditions using a unique integrative approach and a host of modern medical technologies and tools. Dr. Ahvie is a former Clinical Professor of Medicine at UC San Francisco (UCSF) and the personal physician to some of the Bay Area's top biohackers, celebrities, actors, and longevity enthusiasts, along with a wide range of patients looking for eradication of issues like mold, spike protein, fungus, viral particles, and much more. His training includes a medical degree from The Albert Einstein College of Medicine and a Chief Residency in Anatomic Pathology and Internal Medicine, followed by fellowship training in cardiology at The Johns Hopkins Medical Center.  During his 12 years at Johns Hopkins, Dr. Ahvie was co-appointed in the Departments of Medicine and Molecular Immunology and Microbiology. His clinical responsibilities were complemented by directing a multidisciplinary NIH-sponsored research team in the study of molecular immunological and genomic mechanisms of inflammation and cell injury, autoimmunity, transplantation, congestive heart failure, and myocarditis. Today, Dr. Ahvie is back to impart his wealth of knowledge on colon cancer, spanning early detection methods, cancer screening, preventive remedies, and the vital role lifestyle and diet play in managing and preventing this condition. This episode promises a thought-provoking journey into the intricacies of colon health and its profound implications for overall well-being. Full show notes: https://bengreenfieldlife.com/cancerepisode Episode Sponsors: Essentia: Save an additional $100 on your mattress  with code BENVIP at myessentia.com/bengreenfield. LMNT: Go to DrinkLMNT.com/BenGreenfield to get a free gift with your purchase! Calroy: Visit calroy.com/ben save 20% when you bundle a 3-month supply of Arterosil HP. KetoMed: Visit ketomed.com/ben use code Ben40 for $40.00 off, free shipping, and no tax. FUM: Head to tryfum.com/BEN and use code BEN to save an additional 10% off.See omnystudio.com/listener for privacy information.

Ciao ragazzi! Come state??Oggi è il primo venerdì del mese, quindi eccoci qui con una nuova puntata del podcast dedicato all'educazione sanitaria!Nella puntata di oggi tratteremo un argomento di cui avrete di certo già sentito parlare: il sistema immunitario, ovvero quel complesso di meccanismi di difesa che ci protegge ogni giorno contro i microrganismi patogeni e i tumori. Si! Sapevate che il nostro sistema immunitario gioca un ruolo fondamentale anche contro i tumori??Fonti: Libro di testo: Cellular and Molecular Immunology (10th Edition) (Abul K. Abbas, Andrew H. Lichtman, Shiv Pillai) https://www.msdmanuals.com/it-it/professionale https://www.my-personaltrainer.it/fisiologia/immunoglobuline.html https://www.skuola.net/biologia/anatomia-fisiologia/immunita-attiva-passiva.html https://www.nu3.it/blogs/health/rafforzare-sistema-immunitario https://www.focus.it/scienza/salute/cose-che-forse-non-sai-sul-sistema-immunitario https://www.cliccascienze.it/fisiologia/selezione-clonale-linfociti/ Licenza musica:Palm Trees by MBB https://soundcloud.com/mbbofficialQuest'opera è stata rilasciata con licenza Creative Commons Attribuzione - Non commerciale - Condividi allo stesso modo 4.0 Internazionale. Per leggere una copia della licenza visita il sito web http://creativecommons.org/licenses/by-nc-sa/4.0/.

On the latest episode of the Black Health 365 podcast, hosts Jackie and Britt delve into the subject of allergies and their associated symptoms. They are joined by special guest, Dr. Bridgette L. Jones, MD MS who provides expert insight on year-round, seasonal, and food allergies, including their signs, symptoms, and triggers. Dr. Jones also answers common questions about allergies, making this informative episode a must-listen for anyone who experiences allergies. Bridgette L. Jones, MD MS holds a faculty appointment as Professor of Pediatrics at the University of Missouri-Kansas City School of Medicine (UMKCSOM) in the divisions of Allergy/Asthma/Immunology and Pediatric Clinical Pharmacology, Toxicology and Therapeutic Innovation and at Children's Mercy. She is a clinician scientist with a focus in therapeutics and interventions to improve the lives of children with asthma. She holds funding thru the National Institutes of Health and has also received other extramural and intramural resources to support her work. At the UMKCSOM she serves as the Assistant Academic Dean of Student Affairs. At Children's Mercy Dr. Jones is the former medical director of the Office of Equity and Diversity. She started and continues to direct the Children's Mercy Students Training in Academic Research (STAR 2.0) program which introduces high school students from under-represented backgrounds in science and medicine to those fields. Nationally, Dr. Jones is the immediate past Chair of the American Academy of Pediatrics (AAP) Committee on Drugs and the immediate past chair of the American Academy of Allergy Asthma Immunology's Asthma Cough Diagnosis and Treatment Committee. She is currently a member of the National Nominating Committee of the AAP. She is an editorial board member of the Journal of Allergy Asthma and Clinical Immunology in Practice. In addition, she serves as a member of the Food and Drug Administration Pediatric Advisory Committee and was appointed by the United States Secretary of Health to serve on the National Institutes of Health Task Force on Research Specific to Pregnant Women and Lactating Women. She is a standing member for the National Institutes of Health Lung Cellular and Molecular Immunology study section. She is wife to Rafiq and mother to Lola and Nora.See omnystudio.com/listener for privacy information.

References Cellular & Molecular Immunology. 2022. volume 19, pages 1215–1234. Front. Cell Dev. Biol. 2022. 07 January Sec. Epigenomics and Epigenetics # 805195 --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message

Lisa's unending journey for healthy living recently led her to discover Fountain Life, a company dedicated to revolutionizing the healthcare system in order to help people live longer and improve disease detection. It's a lofty mission and one that our guest, Fountain Life's Chief Medical and Science Officer Dr. Helen Messier, says is fundamental to the future of medicine. According to the American Cancer Society about 70% of all cancer deaths come from cancers for which there are currently no proven screening tests. So imagine if we could consistently find cancer at stage zero when it's most easily cured? Fountain Life claims their data-driven approach enables them to find cancer, cardiac, metabolic, and neurodegenerative disease early, before they can cause harm. Dr. Messier received a Bachelor of Science and a PhD in Molecular Immunology from the University of Alberta. She completed post-doctoral studies at the La Jolla Institute for Allergy and Immunology in San Diego, CA and received her MD from the University of Calgary. She's board certified in family medicine. In addition to leading the company's clinical and scientific programs, Dr. Messier will establish Fountain Life University to train Fountain Life certified practitioners and lead the effort to gain insights and publish findings from Fountain Life's vast amount of data. In addition to being related to the Hall of Fame hockey player Mark Messier, she found out on this episode that she's about to be related to the McCaffreys. Listen on for an informative conversation about a critical topic, which ends with a fun reveal. To learn more about Fountain Life's mission, offerings, and locations, visit their website. A reminder that you can watch this episode on our YouTube channel. Thanks as always for listening!

For decades, families have watched Alzheimer's disease steal their loved ones' cognitive function. It's the most common form of dementia; one that affects a third of people over the age of 85. It's a disease Dr. Ron Geyer and Dr. Andrew Kirk want to tackle. Right now, most pharmaceuticals target the symptoms of Alzheimer's disease, without addressing its root cause. Most lose their effectiveness after three months.  Geyer, a biochemist and professor of pathology at the University of Saskatchewan's College of Medicine, said a novel protein could change that. "They did a first clinical trial with this drug and they showed pretty exceptional efficacy," said Geyer. NeuroEPO, first developed by researchers at the Center for Molecular Immunology in Cuba, stimulates red blood cells in the brain. It's a recombinant form of the naturally produced erythropoietin protein (EPO), which stops neuron cells from dying, promoting their growth and communication mechanisms.  During its first round of human trials in early-stage Alzheimer's disease patients, 82 per cent of those receiving the treatment saw stabilization in their cognitive function. For more than half receiving the drug, cognitive function improved.   Alzheimer's disease progressed and worsened for almost everyone receiving the placebo.  "We decided to move this forward and do a Phase Two trial in Canada," Geyer said. Once the study is approved by Health Canada, trials will involve between 80 and 100 patients.  Geyer said so far, everything is on track to begin testing NeuroEPO this summer. The trick, he said, is delivering the drug directly to the brain. "It breaks down in the blood quicker than normal EPO, so that's good in that it doesn't cause side effects," Geyer said.  He said his research group has teamed up with Rocket Science Health Inc., a company that's developed a way to deliver NeuroEPO through the nose to the brain. Compared to a Covid-19 nasal swab, Geyer said the delivery mechanism for this drug is 'much more comfortable'. Working with the Sylvia Fedoruk Canadian Centre for Nuclear Innovation, Geyer said his team is also expanding PET scans and neurological diagnostic tools for patients taking part in the study. "We're hoping that with that, with those diagnostic assays, including MRI to measure the total brain volume, that the clinicians can use this information immediately as the trial starts to better diagnose their Alzheimer's patients, provide more clarity on the diagnosis, let them develop a treatment plan earlier." Geyer said patients and doctors in Saskatchewan have already contacted his team, trying to sign up. "We want to make it as broadly available as possible," he said.  Still, NeuroEPO will not be widely available, until a third-phase trial in the future which proves the drug's efficacy, shows no adverse effects, and involves at least 300-500 patients with Alzheimer's disease.  Geyer said his team is up to the challenge. "It's almost impossible to find someone who doesn't know someone who has some form of dementia," said Geyer. "The ultimate goal is to keep people out of the hospital."      

John MacKenzie chats with Associate Professor Michelle Wykes, Group Leader of Molecular Immunology at QIMR Berghofer Medical Research Institute, about breakthrough cancer research in regard to both breast and bowel cancer. The discovery of a so-called "master switch" is being understood in efforts to potentially turn on vital dendritic cells, which act like the generals of the immune system, to fight particular tumours. "We're seeing palpable tumours that completely disappear and melt away," Michelle Wykes said.

Dr. Robert A. Montgomery, MD, DPhil, FACS, (https://nyulangone.org/doctors/1467404137/robert-montgomery) is the Director of the NYU Langone Transplant Institute, and Chair and a Professor in their Department of Surgery, where he oversees a diverse team of medical and surgical specialists who provide a wide variety of surgery and transplantation services including bone marrow, heart, kidney, liver, lung, and facial transplantation. Dr. Montgomery received his Doctor of Medicine with Honor from the University of Rochester School of Medicine, his Doctor of Philosophy from Balliol College, The University of Oxford, England in Molecular Immunology, and completed his general surgical training, multi-organ transplantation fellowship, and postdoctoral fellowship in Human Molecular Genetics at Johns Hopkins. For over a decade Dr. Montgomery served as the Chief of Transplant Surgery and the Director of the Comprehensive Transplant Center at Johns Hopkins. Dr. Montgomery was part of the team that developed the laparoscopic procedure for live kidney donation, a procedure that has become the standard throughout the world. He and the Hopkins team conceived the idea of the Domino Paired Donation (kidney swaps), the Hopkins protocol for desensitization of incompatible kidney transplant patients, and performed the first chain of transplants started by an altruistic donor. He led the team that performed the first 2-way, 3-way, 4-way, 5-way, 6-way, and 8-way domino paired donations, and in the first 10-way open chain donation. Dr. Montgomery's current research focuses on stem cell therapies and gene- and cell-based therapies in transplantation. He was co-lead of a clinical trial sponsored by the National Institutes of Health involving simultaneous donor bone marrow and live donor kidney transplantation. He also runs multiple clinical trials for novel desensitization therapies. Dr. Montgomery is credited in the 2010 Guinness Book of World Records with the most kidney transplants performed in 1 day, is a world expert on kidney transplantation for highly sensitized and ABO incompatible patients, and is referred the most complex patients from around the globe. Dr. Montgomery has received several awards recognizing his experience in patient care and research, including the American Society of Human Genetics' Postdoctoral Basic Science Award, the Johns Hopkins Clinician Scientist Award, the Fujisawa Faculty Development Award from the American Society of Transplant Surgeons, the Champion of Hope Award from the National Kidney Foundation of Maryland, and the Terasaki Medical Innovation Award from the National Kidney Registry. Dr. Montgomery is also a transplant recipient himself so he has unique perspectives as both patient and clinician.

Parish: St Bede's Catholic Church, Clapham, London Episode 5 – Begins broadcasting on June 17 (Friday) at 8:30pm, June 19 (Sunday) at 4pm and June 20 (Monday) at 10pm Science and Faith on Tour - Season 3 - Faith Journeys in Science - Ep5 Speakers included Fr. Robert Gay and Dr. Szymon Stelter. Robert teaches moral theology and bioethics at Blackfriars Hall and Studium. He is a Governor of the Anscombe Bioethics Centre, and is a member of the Advisory Board for a Catholic Investment Fund. Fr Robert was elected Prior to the Holy Spirit Priory, Oxford, in May 2018. He is also JCR Chaplain and Welfare Officer, providing pastoral and spiritual support to Hall and Studium students. Fr Robert studied biological sciences at Wye College, University of London, before going on to do his doctorate in Plant Physiology at the University of Glasgow. He studied Philosophy and Theology at Blackfriars Studium, and bioethics and medical law at St. Mary's University, Twickenham. His academic interests include the ethics of persistent vegetative state, ethical issues at the end of life, and the use of Thomistic virtue ethics in bioethics. Szmon is a research scientist working in the biotechnology industry in Cambridge. He obtained his PhD in Molecular Immunology from St George's, University of London. Szymon is involved in many evangelising initiatives, like The Word on Fire Institute and Catholic Voices. He also leads a group for young Catholic adults in the local parish. We thank ECLAS for their generosity to make our tour to parishes possible. If you would like to get in touch, email: scienceandfaith@radiomariaengland.uk Facebook/Instagram: @radiomariaengland #RMESCIENCEANDFAITH https://radiomariaengland.uk/science-and-faith-on-tour-season-3-faith-journeys-in-science-ep5/

Dr. John O'Shea is the Scientific Director at the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the NIH, Chief of the branch of Molecular Immunology and Inflammation, and a senior investigator whose lab studies cytokine signaling transduction. Dr. O'Shea earned his bachelor's degree from St. Lawrence University in New York, his MD from the University of Cincinnati, and completed his residency training in internal medicine at SUNY upstate medical center. He then became a fellow at the NIH in the National Institute of Allergy and Infectious Disease, served as a commissioned officer in the US public health service, and ultimately started his own research group at the NIH in 1989. He has made incredible contributions to our understanding of cytokine signaling, including cloning Jak3 and demonstrating its role in the pathogenesis of severe combined immunodeficiency, as well as developing the JAK inhibitor tofacitinib. Outside of science, Dr. O'Shea is an avid musician, and as you will hear – once played alongside Dr. Francis Collins at the Kennedy Center as the opener for Stevie Nicks. Credits: Our thanks to Dr. O'Shea for being on the podcast. Dr. O'Shea's faculty page: https://www.niams.nih.gov/about/niams-leadership/scientific-director-of-intramural-research Host: Bejan Saeedi Co-Host and Audio Engineer – Joe Behnke Executive Producer and Social Media Coordinator – Carey Jansen Executive Producer – Michael Sayegh Faculty Advisor – Dr. Brian Robinson Twitter: @behindthescope_ Instagram: @behindthemicroscopepod Facebook: @behindthemicroscope1 Website: behindthemicroscope.com

Australia is the epicentre of allergies in the world and is on the rise amongst kids and adults alike.  Allergy is problematic for our health because it makes the body feel like it is in a constant state of danger and promotes inflammation. To talk us through why we are seeing such a rise in allergies, all the factors that are contributing to it and the practical things that you can do for yourself and your family to reduce your risk, I had the pleasure of sitting down with one of the leading Allergists in Australia and the world, Professor Pete Smith. Pete commenced his medical studies at the University of Tasmania and went on to specialise in paediatrics in Adelaide, before completing his PhD in molecular immunology at Flinders University. He has worked as an allergy specialist at the Great Ormond Street Hospital for Children in London, and was a senior lecturer at the Institute of Child Health, University College London. In 2002, Pete set up Queensland Allergy Services in Southport, on the Gold Coast, where he provides patients the highest level of quality medical care in the diagnosis and treatment of allergies. Pete is a Professor in Clinical Medicine at Griffith University and Bond University. He currently conducts research studies into the molecular aspects of pain in allergic conditions. Pete is an active member of the Australasian Society of Clinical Immunology & Allergy, and a regular expert commentator in the media. He is a member of the World Allergy Organization, the American Academy of Allergy, Asthma & Immunology, and the European Academy of Clinical Immunology & Allergy.

This interview is with Prof. Christian Eggeling, Professor of Super-resolution Microscopy, Head of Department Biophysical Imaging and Director Institute of Applied Optics and Biophysics at University Jena, as well as Professor of Molecular Immunology at the University Of Oxford. Teledyne Photometrics Web: https://www.photometrics.com/ Twitter: https://twitter.com/Photometrics LinkedIn: https://www.linkedin.com/company/teledynephotometrics/

Seth Lederman is a physician, scientist and founder and executive officer of innovative biopharmaceuticals companies. Prior to founding Tonix, among the companies Dr. Lederman founded was Targent Pharmaceuticals, which developed late-stage oncology drugs, including pure-isomer levofolinic acid (levoleucovorin). Targent’s assets were sold to Spectrum Pharmaceuticals, which marketed levoleucovorin as Fusilev® for advanced colorectal cancer, where it gained significant market acceptance. Dr. Lederman served as an Associate Professor at Columbia University from 1996 until April 13, 2017. He joined the faculty of Columbia University's College of Physicians and Surgeons in 1985, became Assistant Professor of Medicine in 1988, and Associate Professor with tenure in 1996 and Director of the Laboratory of Molecular Immunology in 1997. From 1988 to 2002, Dr. Lederman directed basic science research at Columbia in molecular immunology, infectious diseases and the development of therapeutics for autoimmune diseases. Dr. Lederman is author of numerous scientific articles, and inventor of technologies recognized by a number of issued patents. His fundamental work on the CD40-Ligand (CD154) elucidated the molecular basis of T cell helper function and has led to the development of therapeutic candidates for autoimmune diseases and organ transplant rejection in collaboration with Biogen and UCB. The successful defense of his CD154 patents has led to important precedents in defining the relationship of therapeutics and molecular targets. In collaboration with Prof. David Baltimore (then at Rockefeller University and later MIT), Dr. Lederman identified and functionally characterized the CD40 signaling molecule, TRAF-3. His early work on HIV contributed to the understanding of how the V3 loop of HIV gp120 was involved in fusion with CD4 cell membranes, an early and essential event in viral entry and infection. In addition to his research, Dr. Lederman served as attending physician in the Edward Daniels Arthritis and Autoimmunity Clinic on the Medical Service at Columbia Presbyterian Hospital from 1988-1996. Dr. Lederman represented U.S. Biotechnology at a Beijing Summit in September 2015 with China’s President Xi Jinping. The Summit was organized by the U.S. Chamber of Commerce and involved a delegation of U.S. CEOs, former U.S. Cabinet officials and leading academic experts. Dr. Lederman earned an AB from Princeton in Chemistry cum laude in 1979 and an MD from Columbia University's College of Physicians and Surgeons in 1983. Dr. Lederman trained in internal medicine and rheumatology at Columbia's Presbyterian Hospital. He was an NIH Physician-Scientist 1985-1990 at Columbia.

Gary McLean is a professor in molecular immunology at London Metropolitan University who specialises in infectious diseases, immunology and antibody engineering. He discusses the big international Covid-19 talking points of the week.

Gary McLean is a professor in molecular immunology at London Metropolitan University who specialises in infectious diseases, immunology and antibody engineering. He discusses the big international Covid-19 talking points of the week.

Welcome to this special episode of the Mastin Kipp Podcast! Today’s episode is taken from a live Q&A with Dr. Helen Messier, PhD in Molecular Immunology and MD. Cut through the misinformation about coronavirus and get expert guidance about what to do to stay healthy and reduce anxiety during the COVID-19 pandemic. Take a listen and enjoy!

How amazing would it be to regrow diseased or missing body parts? I am hopeful it will happen someday, but science is not quite there yet. What is more realistic short-term is to teach your body how to heal faster, and that's precisely what Dr. Kaitlyn Sadtler-- an immunologist by trade and former postdoctoral fellow at MIT who’s been selected as one of Forbes 30 Under 30 in science-- is working on. More specifically, her potentially groundbreaking research is focused on how the immune system can regenerate functional tissue. So think of a scar that fully heals itself, leaving that previously wounded area as if nothing happened. Amazing right? It certainly sounds like science fiction but the process of getting to a major breakthrough like this is brutal. Think, lots of failures, dead ends and questions that lead to other questions. It takes something extraordinary to stick with it and in the process of struggle, lies the possibility of breakthroughs. Tune in to learn about what it takes to lead groundbreaking discoveries: What is takes to produce a breakthrough What it's like to be a woman in science How to be with failure What the path to success looks like Connect with Dr. Kaitlyn Sadtler: Linkedin Twitter Website TED Talk   Dr. Kaitlyn Sadtler's biography: Kaitlyn Sadtler, Ph.D. joined NIBIB as an Earl Stadtman Tenure-Track Investigator and Chief of the Section for Immunoengineering in 2019. Prior to her arrival to the NIH, she completed a postdoctoral fellowship at the Massachusetts Institute of Technology with Daniel Anderson, Ph.D. and Robert Langer, Ph.D., focusing on the molecular mechanisms of medical device fibrosis. During her time at MIT, Dr. Sadtler was awarded an NRSA Ruth L Kirschstein Postdoctoral Fellowship, was listed on BioSpace’s 10 Life Science Innovators Under 40 To Watch and StemCell Tech’s Six Immunologists and Science Communicators to Follow. In 2018, she was named a TED Fellow and delivered a TED talk which was listed as one of the 25 most viewed talks in 2018. She was also elected to the 2019 Forbes 30 Under 30 List in Science, selected as a 2020 TEDMED Research Scholar, and received multiple other awards. Dr. Sadtler received her Ph.D. from the Johns Hopkins University School of Medicine where her thesis research was published in Science magazine, Nature Methods, and others. She was recently featured in the Johns Hopkins Medicine Magazine as an alumna of note. Dr. Sadtler completed her bachelor’s degree summa cum laude at the University of Maryland Baltimore County, followed by a postbaccalaureate IRTA at the Laboratory of Cellular and Molecular Immunology at NIAID. * * * Full Transcription: Dr. Kaitlyn Sadtler: If we can understand how the good materials work, then we can engineer further toward really promoting tissue regeneration. Tanya: That’s Dr. Kaitlyn Sadtler, an immunologist by trade and former postdoctoral fellow at MIT who’s been selected as one of Forbes 30 Under 30 in science for her groundbreaking research around how the immune system can regenerate functional tissue. In her TED Talk titled “How We Could Teach Our Bodies to Heal Faster,” she shares details on her research findings, which resonated with millions. More recently, Dr. Kaitlyn Sadtler was hired by the National Institutes of Health to lead her own lab and pursue scientific breakthroughs in her field. You have a very interesting segue into the sciences and laboratory space and academia, really. You started off as a veterinarian technician. How was that experience like? Dr. Kaitlyn Sadtler: I had, really, a great opportunity growing up. I grew up about three miles away from a veterinary clinic back in rural Maryland, and I actually started working there when I was in high school. At the beginning of that, as opposed to what you think of with veterinary technicians drawing blood, things like that,

John J. O’Shea, MD, is scientific director of the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases, and chief of their Molecular Immunology and Inflammation Branch. In this ACR interview, he joins me to talk about the JAK/STAT pathway, what we’ve learned from mouse models, current FDA-approved JAK inhibitors and the future of this exciting field. Intro :10 Background on Dr. O’Shea :45 The interview 2:37 How did you start looking into the JAK/STAT pathway? 3:16 What should a clinician understand about this pathway? 5:22 What do these cytokines have in common? 6:37 What have we learned from mouse models? 8:48 GWAS studies in JAK/STAT 11:49 Can we quantify how much a certain cytokine may be using this pathway? 12:39 Can you explain suppressor of cytokine signaling, aka SOCS? 14:15 What do we know about how these different cytokines can have individual signaling controls? 16:40 An explanation of phenocopy 18:01 What evidence do we have that JAK may circumvent STAT, and vice versa? 18:41 An overview of FDA-approved JAK inhibitors and the pipeline 20:52 What excites you the most about the future of this field? 23:26 In a state of wonder over success of biologics 25:50 Thank you, Dr. O’Shea 27:20 Recap 27:30 We’d love to hear from you! Send your comments/questions to rheuminationspodcast@healio.com. And be sure to follow us on Twitter @AdamJBrownMD and @HealioRheum. This information is brought to you by Healio and is not sponsored by, nor a part of, the American College of Rheumatology.

Welcome to the RVC research podcast, where we are joined by Dirk Werling, Professor of Molecular Immunology about the microbiome and why we should all be interested in it. We hope that you enjoy listening to our conversation as much as we enjoyed recording it. To find out more about Prof Werling’s work, use the following link  https://www.rvc.ac.uk/about/our-people/dirk-werling   If you have any comments about this podcast, please get in touch: email dbarfield@rvc.ac.uk; tweet @dombarfield. We would greatly appreciate your time to rate us on Apple podcast or Acast and kindly write us a review.

Welcome back to Five Minutes, the podcast series where we speak to the most interesting people in the world of malaria. Today I’m really excited to be joined by Dr Michelle Wykes all the way from Brisbane, Australia. She runs the Molecular Immunology unit at QIMR Berghofer Medical Research Institute and has been focusing on trying to improve the immune system’s response to a malaria infection. We discuss her recent work in malaria research which has been hailed as a breakthrough.

Georgina Ferry interviews Neil Barclay. Neil Barclay is Emeritus Professor of Chemical Pathology in the Dunn School. He arrived in Oxford as an undergraduate in 1969 to study Biochemistry, and undertook a DPhil in the same department supervised by Alan Williams. After a post-doctoral position in Sweden, he returned to Oxford to work on monoclonal antibodies with Williams, who had just been appointed head of the MRC Cellular Immunology Unit within the Dunn School. Barclay pioneered the sequencing of proteins on the surface of cells of the immune system that had been isolated through the use of monoclonal antibodies. In 2010 he succeeded George Brownlee as EP Abraham Professor of Chemical Pathology. He set up the CIU Trust to manage royalties from sales of monoclonal antibodies generated within the Cellular Immunology Unit, and through this has partially endowed the Barclay Williams Chair in Molecular Immunology. He is also Chair of the EPA Cephalosporin Fund, and has founded a company, Everest Biotech, that is based in Nepal and uses goats to generate antibodies against human proteins for research.

In this week’s Success Story, Professor Gabrielle Belz, an award-winning scientist and Laboratory Head of the Molecular Immunology division at The Walter and Eliza Hall Institute of Medical Research (WEHI) explains to Catherine Robson the importance of nurturing a healthy gut, shares career advice for young scientists and her productivity hacks for managing the ‘reasonably unreasonable’ time demands of a career in science.

Welcome back to the RVC podcast, where we are going to focus on the researchers and their research. For our 51st episode we talk to Dirk Werling, Professor of Molecular Immunology about how he started his research career, what research he is currently involved with and advice to those people interested in pursuing a career in research. We hope that you enjoy listening to our conversation as much as we enjoyed recording it. To find out more about Prof Werling’s work, use the following link  https://www.rvc.ac.uk/about/our-people/dirk-werling   If you have any comments about this podcast, please get in touch: email dbarfield@rvc.ac.uk; tweet @dombarfield. We would greatly appreciate your time to rate us on Apple podcast or Acast and kindly write us a review.

Dr Christian Eggeling tells us how new imaging methods help us understand immunology at the molecular level. To study complex biological and immunological systems, such as living cells, scientists rely on highly sensitive and non-invasive analysis techniques. Super-resolution optical microscopy allows us to study immunological processes on the molecular level. We can get new insights into how our body reacts to viral or bacterial attacks. Dr Christian Eggeling's research focuses on the application and development of superior, ultra-sensitive, live-cell fluorescence microscopy techniques. This has the potential to help us design new drugs and developing new ways of treating diseases.

Dr Christian Eggeling tells us how new imaging methods help us understand immunology at the molecular level. To study complex biological and immunological systems, such as living cells, scientists rely on highly sensitive and non-invasive analysis techniques. Super-resolution optical microscopy allows us to study immunological processes on the molecular level. We can get new insights into how our body reacts to viral or bacterial attacks. Dr Christian Eggeling's research focuses on the application and development of superior, ultra-sensitive, live-cell fluorescence microscopy techniques. This has the potential to help us design new drugs and developing new ways of treating diseases.

Dr Christian Eggeling tells us how new imaging methods help us understand immunology at the molecular level. To study complex biological and immunological systems, such as living cells, scientists rely on highly sensitive and non-invasive analysis techniques. Super-resolution optical microscopy allows us to study immunological processes on the molecular level. We can get new insights into how our body reacts to viral or bacterial attacks. Dr Christian Eggeling's research focuses on the application and development of superior, ultra-sensitive, live-cell fluorescence microscopy techniques. This has the potential to help us design new drugs and developing new ways of treating diseases.

Dr Christian Eggeling tells us how new imaging methods help us understand immunology at the molecular level. To study complex biological and immunological systems, such as living cells, scientists rely on highly sensitive and non-invasive analysis techniques. Super-resolution optical microscopy allows us to study immunological processes on the molecular level. We can get new insights into how our body reacts to viral or bacterial attacks. Dr Christian Eggeling's research focuses on the application and development of superior, ultra-sensitive, live-cell fluorescence microscopy techniques. This has the potential to help us design new drugs and developing new ways of treating diseases.

Special Guest:  Helene Belisle, Arthritis National Research Foundation Executive Director. Helene Belisle has been Executive Director of the Arthritis National Research Foundation since 1996, helping guide the organization to its current focus funding arthritis research grants nationwide. Ms. Belisle joined ANRF after four years in fundraising for a Long Beach, CA non-profit organization. For many years prior to entering the non-profit field, Ms. Belisle was a marketing executive for a real estate investment firm. Special Guest: Dr. Carl Ware has been a Member and Head of the Division of Molecular Immunology at the LaJolla Institute for Allergy & Immunology since 1996. He received his Ph.D. in 1979 from the University of California, Irvine, and conducted his postdoctoral work at the University of Texas and the Dana-Farber Cancer Institute, Harvard Medical School in Boston. He established his research laboratory in 1981 as an Assistant Professor of Immunology at the University of California, Riverside, advancing to full professor before joining the La Jolla Institute for Allergy and Immunology.   www.curearthritis.org